智通财经网·2025-10-26 08:13Core Viewpoint - WuXi AppTec (603259.SH) announced the sale of 100% equity in two subsidiaries, Shanghai Kande Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd., for a base price of RMB 2.8 billion, aiming to focus on its CRDMO business model and enhance global capabilities and capacity [1][2]. Group 1 - The transaction involves the complete transfer of equity in both target companies as an indivisible part of a comprehensive deal [1]. - The sale aligns with the company's strategy to concentrate on drug discovery, laboratory testing, and process development and production services [2]. - The target companies generated approximately RMB 1.16 billion in revenue from January to September 2025, accounting for about 3.5% of the company's total revenue for the same period [2]. Group 2 - The net profit of the target companies for the same period was approximately RMB 90 million, representing about 0.7% of the company's net profit [2]. - The transaction is expected to provide financial support for the company's accelerated global capacity deployment [2].